Sign inJoin waitlistJoin the waitlist

Ursula Matulonis

Brock-Wilson Family Chair · Mass General Brigham

Credentials: · · ·

History

Mass General Brigham
Present
Division of Gynecologic Oncology · Mass General Brigham
Present
division of · Mass General Brigham
Present

Research

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
New England Journal of Medicine · 2016 · 2,004 citations
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
New England Journal of Medicine · 2012 · Last of 15 authors · 1,485 citations
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised…
The Lancet Oncology · 2014 · Last of 18 authors · 1,155 citations

Joyce Liu
88 papers · 2 as a fellow
Panagiotis Konstantinopoulos
77 papers
RP
Richard Penson
54 papers
Susana Campos
50 papers
Neil Horowitz
42 papers · 3 as a fellow
Alexi Wright
33 papers
Carolyn Krasner
32 papers
Michael Birrer
29 papers
Ross Berkowitz
25 papers
David O'Malley
24 papers
MS
Michael Seiden
24 papers
Elizabeth Stover
22 papers · 2 as a fellow

Grants

Targeting Replication Stress and DNA Damage Response in Uterine Cancer
National Cancer Institute · P01
Contact PI · $8.9M · Dana-Farber Cancer Inst
2024–2029
Dana-Farber/Harvard Cancer Center
National Cancer Institute · P30
Project lead · $208.6K · Dana-Farber Cancer Inst
1997–2026
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE Grant
National Cancer Institute · P50
PI · $11.5M · Dana-Farber Cancer Inst
2020–2025

Clinical trials

A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Principal investigator · Completed · Phase 3
ImmunoGen, Inc.
2020–2022
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
Principal investigator · Completed · Phase 1, Phase 2
Syndax Pharmaceuticals
2016–2021
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute
2016–2022
GSK1120212+GSK2141795 for Cervical Cancer
Principal investigator · Terminated · Phase 2
Dana-Farber Cancer Institute
2013–2017